Description: Canntab Therapeutics Limited, a biopharmaceutical company, engages in the research and development of advanced pharmaceutical grade formulations of cannabinoids, tetrahydrocannabinol, and terpenes in Canada. It offers oral dosage formulations of pharmaceutical cannabis, including sustained release cannabinoid formulations and pellets, immediate release cannabidiol formulations, modified-release multi-layer cannabinoid formulations, flash-melt cannabinoid formulations, and bi-layer cannabinoid tablets for treating sleep disorders, post-traumatic stress disorder, social anxiety, addiction, arthritis, general pain, pain management and appetite loss associated with cancer treatments, and addiction treatment therapy of opioids and other painkillers. Canntab Therapeutics Limited is headquartered in Markham, Canada.
Home Page: canntab.ca
223 Riviera Drive
Markham,
ON
L3R 5J6
Canada
Phone:
289 301 3812
Officers
| Name | Title |
|---|---|
| Mr. Richard C. Goldstein | Interim CEO, Co-Founder, CFO & Director |
| Mr. Barry M. Polisuk B.A., LL.B | Sec. & Independent Director |
| Mr. Joshi Laxminarayan | Chief Scientific Officer |
| Mr. Eric Malinski | Director of Marketing |
Exchange: PINK
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.7425 |
| Price-to-Sales TTM: | 1.8319 |
| IPO Date: | |
| Fiscal Year End: | May |
| Full Time Employees: | 0 |